Effect of the combination of antiplatelet agents in man : Combination of aspirin, trapidil, ticlopidine and dipyridamole

Association of Recurrent Cerebral Infarction With Adenosine Diphosphate– and Collagen-Induced Platelet Aggregation in Patients Treated With Ticlopidine and/or Aspirin

“…[5][6][7][8][9] This implies that the platelet aggregation test can reflect the inhibitory effect of antiplatelet drugs when appropriate agonists are used. In the aspirin group, the recurrence rate tended to be higher (but not statistically significantly so) in the higher collagen-induced aggregation quartiles.…”

“…Collagen-induced platelet aggregation is more strongly inhibited by aspirin than by trapidil, ticlopidine, or dipyridamole. 5 Although a low dose of aspirin is able to inhibit collagen-induced platelet aggregation, a high dose is needed to inhibit adenosine diphosphate (ADP)-induced platelet aggregation. 6 Meanwhile, ADP-induced platelet aggregation is markedly inhibited by the thienopyridine derivatives ticlopidine and clopidogrel.…”

ADP Receptor Antagonism

“…Ticlopidine in ic hemostasis and thrombosis. [7,8] This biologic effect was explored in a clinical types in the platelet membrane: the guanosine triphosphate (GTP) setting involving patients undergoing coronary stenting for whom coupled protein receptors known as G-protein binding sites and the antithrombotic regimen of choice for prevention of stent the ligand-gated ion channel. [7,8] This ADP is not only released from intracellular storage granules but property is attributed to the synergistic effects obtained on platelet also further activates platelets, amplifying the activation and thus inhibition through blockade of two different pathways, COX-1 aggregation processes.…”

“…[11] antagonists. [7,8] This article reviews the current knowledge of platelet ADP P2Y12 receptor antagonism Thienopyridines represent the first family of ADP receptor and the projected developments in this field. Thienopyridines: Exploring the Good and the Bad cesses through ADP receptor blockade.…”

“…[7,8] Their introduction into clinical practice occurred several years before knowledge of the specific ADP receptor subtype they inhibited (the P2Y 12 receptor). [7,8] Their introduction into clinical practice occurred several years before knowledge of the specific ADP receptor subtype they inhibited (the P2Y 12 receptor).…”